Immuno oncology News and Research

RSS

Researchers identify key protein required for optimal immune responses to cancer

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.

2 Jun 2020

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.

2 Jun 2020

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

30 May 2020

Bioinsider launches COVID-19 virtual meeting series

Bioinsider has opened registration and a call for speaker proposals for its four-part virtual meeting series, Together as One COVID-19 Series.

21 May 2020

Finnish research in cancer immunotherapy receives 10 million euros

Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland's Personalized Health Program.

11 May 2020

Sartorius launches the new Incucyte SX5® for live-cell analysis, offering new possibilities for live-cell analysis experiments

Sartorius, a leading international supplier for the biopharmaceutical industry, today launched the new Incucyte SX5 Live-Cell Analysis System, the latest in the company’s line of live-cell analysis products.

From Sartorius 5 May 2020

New 'Immuno-Engineering to Improve Immunotherapy' Center formed to advance cancer therapy

Harvard University's Wyss Institute of Biologically Inspired Engineering and its collaborating institutions, the Harvard John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Harvard's Department of Stem Cell and Regenerative Biology, announce the formation of a new NIH-funded Immuno-Engineering to Improve Immunotherapy Center.

7 Mar 2020

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.

27 Feb 2020

Isolating Single T-cells of Interest using an Optofluidic Platform

Researchers are in desperate need of single-cell analysis techniques and those that allow the isolation of high-value T-cells for research and development.

From Bruker Cellular Analysis 21 Feb 2020

Determining Microsatellite Instability Status Using Multiplex PCR-Based Methods

Determining microsatellite instability status using multiplex PCR-based methods used to screen for Lynch Syndrome, a dominant hereditary cancer propensity.

From Promega Corporation 24 Jan 2020

MIT spin-out partners with Cambridge Consultants to co-develop the first Flowfect system

MIT spin-out company Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect system.

22 Jan 2020

Study reveals how clotting protein and blood platelets promote immune evasion, tumor progression

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute reveals how a clotting protein and blood platelets can promote cancer progression and suppress immune responses to cancer.

14 Jan 2020

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Pathios Therapeutics Limited, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialization Fund managed by Brandon Capital.

9 Jan 2020

Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programs.

From PhoreMost 7 Jan 2020

Phase II case-control trial initiated for four types of terminal cancers

The Alexandrov National Cancer Centre begins phase II case-control clinical trial of its immuno-oncology agent, Elenagen.

7 Jan 2020

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

From FairJourney Biologics 4 Dec 2019

PREDiCT: Tumor Models San Francisco Summit 2020

The community of preclinical immuno-oncology scientific Pharma and Biotechs meet again to advance their preclinical insights through robust models utilization to accelerate IO development & clinical confidence.

25 Nov 2019

HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy

The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.

5 Nov 2019

Oncolytics Biotech and PrECOG collaborate to study metastatic breast cancer

Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study.

22 Oct 2019

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019